Cancer Supportive Care Drugs Market Analysis

Global Cancer Supportive Care Products Market is estimated to be valued at US$  32,458.0 in 2023 and is expected to exhibit a CAGR of 4.7% during the forecast period (2023-2030). Cancer-supportive care products can be defined as products or drugs that are mainly used for the treatment of adverse effects associated with cancer therapy as well as for the treatment of symptoms and signs of cancer such as nausea, vomiting, hair loss, low blood counts, and others.

Analysts’ Views on Global Cancer Supportive Care Products Market :

Increasing demand of the global cancer supportive care products has created huge opportunities for the growth of the market expansion. These are important drivers of market expansion. For instance, In 2020, according to the World Cancer Research Fund International (WCRF), it has been observed that in 2035 there will be more than 24 mn cases of cancer.

Figure 1. Global Cancer Supportive Care Product Market  Share (%),By Drug Class, 2023

Global Cancer Supportive Care Product  Market- Driver

Increasing Demand for Cancer Supportive Care Product Market -

High prevalence of cancer is likely to boost the demand for cancer-supportive care products. This in turn drives the growth of the market. For instance, In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer deathMoreover, increasing funding in cancer Research & Development is also expected to aid in the growth of the global cancer supportive care products market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 mn in 2018/19.North America held a dominant position in the global cancer supportive care products market in 2022, accounting for a 36.5% share in terms of value, followed by Europe and Asia Pacific, respectively.

Launch of new products  -

Increasing the amount of money spent on doing research and development for cancer is resulted into the launch of innovative products. For instance, in 4 May 2022, Trastuzumab was approved for patients with unresectable or metastatic HER2- positive breast cancere who have received a prior anti –HER2—based regimen either in the metastatic setiing or in  the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 mont sof completing therapy.

Cancer Supportive Care Product Market Report Coverage

Report Coverage	Details
Base Year:	2022	Market Size in 2023:	US$ 32,458.0 Mn
Historical Data for:	2017 to 2021	Forecast Period:	2023 to 2030
Forecast Period 2023 to 2030 CAGR:	4.7%	2030 Value Projection:	US$ 44,915.7 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor By Indication: Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, and Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies
Companies covered:	Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa Hakko Kirin Co., Ltd.
Growth Drivers:	Increasing Demand for Cancer Supportive Care Product Market  Launch of new products
Restraints & Challenges:	Loss of brands exclusivity of various generic drugs

Figure 2. Global Cancer Supportive Care Product Market Share (%), By Region, 2023

Global Cancer Supportive Care Product Market - Regional Analysis

Among regions, North America is expected to dominate the market over the forecast period, due to the increasing demand for the cancer related products and because of this there is wide  opportunities for public and private sectors operations. For instance, in January 2020, the Global Cancer Program hosted the "UCSF-Mexico Cancer Collaboration Annual Meeting" with partners, such as Instituto Nacional Cancerologia (INCan), Instituto Nacional de Salud Pública (INSP), and the Instituto Nacional de Medicina Genómica (INMEGEN). The UCSF-Mexico Cancer Initiative aims to strengthen regional cancer research capacity and expand the institutional cancer research portfolios and training activities of partners in Mexico. Thus, the high prevalence and growing research funding for cancer research is expected to drive the growth of the cancer vaccines market.

Global Cancer Supportive Care product Market- Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic had a negative impact on the Global Cancer Supportive Care Market because it leads to increased risk for the people suffering for cancer and dying from SARS-COV-2 infection. For instance, in June 2020, the National Health Service (NHS) released statistics for April 2022 indicating that 60% of the urgent diagnosis of cancer had fallen also some cancer surgical procedures have been postponed.

Global Cancer Supportive Care product Market Segmentation:

The Global Supportive Care Market report is segmented into Drug Class, Indication, Distribution Channel and Region.

Based on Drug Class, the market is segmented into Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor.Out of which Nonsteroidal Anti- Inflammatory Drugs is expected to hold a dominant position in the cancer supportive care product market during the forecast period. For instance, according to the cross-sectional study of article About 65.1% of the participants agreed that they have taken Nonsteroidal Anti- Inflammatory Drugs in any form with 6.7% of them taking it regularly. The frequency of taking Nonsteroidal Anti- Inflammatory Drugs without a medical prescription was found to be 45.5%. Heartburn (46.6%) was a common complication related to Nonsteroidal Anti- Inflammatory Drugs usage followed by peptic ulcer diseases (45.2%). The commonly consumed NSAID was Ibuprofen (45.2%).

Based on Indication, the market is segmented into Lung Cancer, Breast cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others. Out of which Lung cancer is expected to hold a dominant position in the cancer supportive care product market during the forecast period.For instance, in 2023, according to American Cancer Society’s in U.S. about 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and  about 127,070 deaths from lung cancer (67,160 in men and 59,910 in women) is observed.

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies. Out of which Hospital Pharmacies is expected to hold a dominant position in the cancer supportive care product market during the forecast period.For instance, according to BMJ Publishing Group ,in 2022, availability of anti-neoplastic essential medicines(Ems) was 38% in private-sector retail pharmacies, 43% in public hospital pharmacies and 71% in private hospital pharmacies. Median MPR of lowest-priced generic versions was 0.71 in retail pharmacies. 

Based on Region, the North America is expected to hold a dominant position in the cancer supportive care product market during the forecast period. For instance, according to cancer facts and figures 2021 published in the American Cancer Society journal, there is 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States.

Global Cancer Supportive Care Product Market  - Cross Sectional Analysis:

 North America has the largest share of the global cancer supportive carer product market which owns huge investments made in U.S. US region acts as the major revenue generator followed by Canada. Due to the large investments in the oncology sector and also due to the presence of the pharmaceutical giants U.S. region is the dominant globally. Among every 100,000 population 436 new cases were reported and about 156 died of cancer in the same year. Because of the increase in the incidence of the cancer cases the vendors invest in the research and development activities.     

Global Cancer Supportive Care Product Market: Key Developments

• Major players in the market are focused on presenting new portfolios in order to enhance their market share. For instance, in September 2020, Merck a global pharmaceutical, chemical and life science company with a history that began in 1668 and a future shaped by approximately 50,000 employees in 66 countries . Merck announced that more than 30 abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21. The abstracts span the company's clinical program in oncology across several innovative modalities and mechanisms that have the potential to advance treatment across a range of tumor types including biliary tract, lung, and urothelial (bladder) cancers.
• In 28 December 2022, U.S. Food and Drug Administration (FDA) approved immunotherapy drug atezolizumab (Tecentriq) for the treatment of adults and children 2 years and older with Alveolar soft part sarcoma (ASPS) that has spread to other parts of the body or cannot be removed by surgery.
• In 21 March 2020, National Cancer Institute has launched the Molecular Characterization Initiative for pediatric tumors. This program offers tumor molecular characterization, also called biomarker testing, to children, adolescents, and young adults with newly diagnosed central nervous system tumors who are being treated at hospitals that are affiliated with the Children’s Oncology Group (COG)

Global Cancer Supportive Care Product Market: Restraint

Loss of brand exclusivity of various generic drugs is expected to hinder the growth of the global cancer supportive care products market.

Moreover, the entry of biosimilars is also expected to limit the growth of the global cancer supportive care products market. Patents for certain major drugs used in cancer supportive care products have expired or are expected to expire in the near future. This is projected to open the gateway for biosimilars for anti-cancer therapy, which would lead to a drastic decrease in the prices of patent-expired drugs.

Global Cancer Supportive Care Product Market:Opportunities

Increasing investment in the pharmaceutical sector is expected to offer lucrative growth opportunities for players in the global cancer supportive care products market.

Moreover, R&D in cancer pain care is also expected to offer lucrative growth opportunities for players in the global cancer supportive care products market. For instance, in September 2020, EMD Serono the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, presented its oncology portfolio and pipeline in supportive care in multiple cancers at ESMO 2020.

Global Cancer Supportive Care Product Market: Competitive Landscape

Major players operating in the global cancer supportive care products market include, Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono.

 Definition: Cancer supportive care is associated with care given to patients suffering from various types of cancer. Supportive care is intended for relieving the suffering of the patients and improving their quality of life. The motive behind the supportive care is to improve the quality of life of the patient. Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. The high prevalence of cancer, increasing research and development along with increasing investment in the biopharmaceutical industry is anticipated to drive the market growth during the forecast period.